Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today the
appointments of Brett Kaplan, M.D., as Chief Operating Officer, and
Nishi Rampal, M.D., as Senior Vice President, Clinical Development.
“I am delighted to announce the addition of Brett and Nishi to
our executive team,” said Dr. Aoife Brennan, CEO of Eliem
Therapeutics. “Since completing the Tenet Medicines acquisition, we
have worked diligently to build a best-in-class management team as
we transition Eliem into a leading biotechnology company. Brett and
Nishi represent two critical additions to the Eliem team. Brett has
demonstrated exceptional financial and operational leadership
throughout his career. Nishi brings an impressive track record in
leading clinical development strategy, from bench to launch, across
a variety of therapeutic areas, including key focus areas we plan
to pursue at Eliem. We look forward to leveraging their expertise
and insights as we grow Eliem and advance our pipeline focused on
developing therapeutics for autoimmune-driven inflammatory
diseases.”
“I could not be more excited to be joining Eliem at this
juncture in its evolution,” said Dr. Kaplan. “I look forward to
working with the team to strengthen key areas of the business,
positioning the Company for sustained success. Our commitment to
advancing the organization will give us the potential to develop a
pipeline of transformative therapies.”
“Many patients with autoimmune diseases face suboptimal
treatments,” said Dr. Rampal. “Eliem’s lead asset, budoprutug
(previously referred to as TNT119), represents a potentially
best-in-class anti-CD19 antibody with broad applications across a
number of autoimmune diseases. I am inspired by Eliem’s mission and
excited to advance the development of antibody-based therapies to
address these unmet medical needs.”
Brett Kaplan, M.D., Chief Operating OfficerDr.
Kaplan has over 20 years of finance and operations leadership in
biotechnology and investment banking. Before joining Eliem, Dr.
Kaplan served as President, Chief Financial and Corporate
Development Officer at Chroma Medicine Inc., where he raised
approximately $250 million to fund the research and development of
epigenetic editors, a new class of genomic medicines. Prior to
Chroma, Dr. Kaplan was the Chief Financial Officer of Prevail
Therapeutics, which was acquired by Eli Lilly and Company for $940
million. At Evercore Partners, Dr. Kaplan was a Managing Director,
Investment Banking advising on strategic and financing
transactions. Dr. Kaplan has held other corporate development and
strategy positions at Cubist Pharmaceuticals, a pharmaceutical
company acquired by Merck & Co., Inc., Biopure Corporation, and
Eli Lilly. Dr. Kaplan is currently a director of Myeloid
Therapeutics, Inc. and also served as a director of Compass
Therapeutics, Inc. Dr. Kaplan holds an MBBCh. and an M.B.A. from
the University of Witwatersrand.
Nishi Rampal, M.D., Senior Vice President, Clinical
DevelopmentDr. Rampal brings over 10 years of extensive
experience in the pharmaceutical and biotechnology industries with
a track record of leadership in rare disease drug development,
spanning neurology, rheumatology, dermatology, and hematology. Over
the course of her career in industry, she has led programs
resulting in successfully global approvals including UPLINZA®
(inebilizumab-cdon), a groundbreaking treatment for neuromyelitis
optica spectrum disorder and ULTOMIRIS (ravulizumab-cwvz) a
treatment for myasthenia gravis. Prior to Eliem, Dr. Rampal was the
Executive Director Clinical Development at Horizon Therapeutics
(acquired by Amgen, Inc. for $27.8 billion in October 2023), where
she was the global lead on the development and strategy for
UPLINZA. Prior to Amgen, Dr. Rampal was a Medical Director Clinical
Development at Alexion Pharmaceuticals (acquired by AstraZeneca for
$39 billion in December 2021). While at Alexion, Dr. Rampal worked
on the global pivotal Phase 3 trial for ravulizumab (Ultomiris),
CHAMPION® developed for myasthenia gravis. Dr Rampal completed her
neurology residency at the Yale School of Medicine and her
neurophysiology and epilepsy fellowship at Columbia University, and
is double board certified with past academic appointments at Yale
University, Columbia University, and Mount Sinai Icahn Schools of
Medicine.
About Eliem Therapeutics,
Inc.Eliem Therapeutics is focused on developing
therapeutics for autoimmune-driven inflammatory diseases, including
advancing budoprutug, an anti-CD19 antibody designed for a broad
range of autoimmune diseases, including systemic lupus
erythematosus, lupus nephritis, immune thrombocytopenia and
membranous nephropathy. For more information, please visit
https://eliemtx.com/
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation statements regarding: future
expectations, plans and prospects for Eliem; the anticipated
benefits of the acquisition of Tenet Medicines, Inc.; the strategy,
anticipated milestones and key inflection points for Eliem; Eliem’s
budoprutug product candidate, including expectations regarding
budoprutug’s therapeutic benefits, clinical potential and clinical
development and other statements containing the words “anticipate,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intend,”
“may,” “plan,” “potential,” “predict,” “project,” “should,”
“target,” “would,” “will,” “working” and similar expressions. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in, or implied by,
such forward-looking statements. Eliem may not actually achieve the
plans, intentions or expectations disclosed in these
forward-looking statements, and you should not place undue reliance
on these forward-looking statements. These risks and uncertainties
include, but are not limited to, important risks and uncertainties
associated with: the ability of the Eliem to timely and
successfully achieve or recognize the anticipated benefits of the
acquisition; changes in applicable laws or regulation; the
possibility that Eliem may be adversely affected by other economic,
business and/or competitive factors; Eliem’s ability to advance
budoprutug and/or its other product candidates on the timelines
expected or at all and to obtain and maintain necessary approvals
from the U.S. Food and Drug Administration and other regulatory
authorities; obtaining and maintaining the necessary approvals from
investigational review boards at clinical trial sites and
independent data safety monitoring board; replicating in clinical
trials positive results found in early-stage clinical trials of
budoprutug; competing successfully with other companies that are
seeking to develop treatments for systemic lupus erythematosus and
lupus nephritis, immune thrombocytopenia and membranous nephropathy
and other autoimmune driven inflammatory diseases; maintaining or
protecting intellectual property rights related to budoprutug
and/or its other product candidates; managing expenses; and raising
the substantial additional capital needed, on the timeline
necessary, to continue development of budoprutug and other product
candidates Eliem may develop. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause Eliem’s actual results to differ materially from those
contained in the forward-looking statements, see the “Risk Factors”
section, as well as discussions of potential risks, uncertainties
and other important factors, in Eliem’s most recent filings with
the SEC. In addition, the forward-looking statements included in
this press release represent Eliem’s views as of the date hereof
and should not be relied upon as representing Eliem’s views as of
any date subsequent to the date hereof. Eliem anticipates that
subsequent events and developments will cause Eliem’s views to
change. However, while Eliem may elect to update these
forward-looking statements at some point in the future, Eliem
specifically disclaims any obligation to do so, except as required
by law.
InvestorsChris Brinzey ICR
Westwickechris.brinzey@westwicke.com339-970-2843
Eliem Therapeutics (NASDAQ:ELYM)
Historical Stock Chart
From Sep 2024 to Oct 2024
Eliem Therapeutics (NASDAQ:ELYM)
Historical Stock Chart
From Oct 2023 to Oct 2024